REG - Oxford Biomedica PLC - Market Share Purchase

Oxford BioMedicaAnnouncement

31/01/2022 11:25

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220131:nRSe1612Aa&default-theme=true

RNS Number : 1612A  Oxford Biomedica PLC  31 January 2022

 

 

Market Share Purchase

 

London, UK - 31 January 2022: Oxford Biomedica plc ("Oxford Biomedica" or the
"Company") (LSE:OXB), a leading gene and cell therapy group, was informed that
Matthew Treagus, Chief Information Officer, has purchased 594 ordinary shares
of 50p each ("Ordinary Shares") in the Company on 28 January 2022 on the
London Stock Exchange at a price of 841.7p. Following this purchase Matthew
Treagus holds 4,501 Ordinary Shares representing 0.005% of the Company.

 

The below notification, made in accordance with the requirements of the EU
Market Abuse Regulation, gives further detail of the number of ordinary shares
purchased.

 

 

 1.  Details of the Person Discharging Managerial Responsibility ("PDMR")/person
     closely associated with them ("PCA")
 a)  Name                                     Matthew Treagus
 2.  Reason for the notification
 a)  Position/status                          Chief Information Officer

 b)  Initial notification/                    Initial Notification

     amendment
 3.  Details of the Issuer
 a)  Name                                     Oxford Biomedica plc
 b)  LEI code                                 213800S1GVQNXQ15K851
 4.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument  Ordinary Shares of 50 pence each

     Identification code                      ISIN: GB00BDFBVT43
 b)  Nature of the transaction                Purchase
 c)  Price(s) and volumes(s)

Price(s)  Volume(s)
                                              £8.417    594
 d)  Aggregated information

     ·      Aggregated volume                 594

     ·      Price

     ·      Aggregated total                   £8.41664

                                               £4,999.48

 e)  Date of the transaction                  01-28-2022
 f)  Place of the transaction                 London Stock Exchange, Main Market (XLON)

d)

Aggregated information

·      Aggregated volume

·      Price

·      Aggregated total

 

 

594

 

 £8.41664

 £4,999.48

 

e)

Date of the transaction

01-28-2022

f)

Place of the transaction

London Stock Exchange, Main Market (XLON)

 

 

 

-Ends-

 

 For further information, please contact:

 Oxford Biomedica plc:                     Tel: +44 (0)1865 783 000

 Natalie Walter, Company Secretary

 

 

About Oxford Biomedica

 

Oxford Biomedica (LSE: OXB) is a leading, fully integrated, gene and cell
therapy group focused on developing life changing treatments for serious
diseases. Oxford Biomedica and its subsidiaries (the "Group") have built a
sector leading lentiviral vector delivery platform (LentiVector®), which the
Group leverages to develop in vivo and ex vivo products both in-house and with
partners. The Group has created a valuable proprietary portfolio of gene and
cell therapy product candidates in the areas of oncology, CNS disorders and
liver diseases. The Group has also entered into a number of partnerships,
including with Novartis, Bristol Myers Squibb, Sio Gene Therapies, Orchard
Therapeutics, Santen, Beam Therapeutics, Boehringer Ingelheim, Arcellx and
Cabaletta Bio,through which it has long-term economic interests in other
potential gene and cell therapy products. Additionally, the Group has signed a
3-year master supply and development agreement with AstraZeneca for
large-scale manufacturing of the adenoviral based COVID-19 vaccine, AZD1222.
Oxford Biomedica is based across several locations in Oxfordshire, UK and
employs more than 740

people. Further information is available at www.oxb.com
(https://protect-eu.mimecast.com/s/E-ccCLZMpFRYEyOIB1GH-)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHUAAARUNUAOAR